Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
Dual-Target CAR T Cells Achieve 100% Response Rate in MM
Metabolic Dysfunction–Associated Steatotic Liver Disease Linked With CRC